Introduction: The Unmet Need for Contrast-Free Abdominal Imaging

Magnetic Resonance Imaging (MRI) has become an indispensable tool for evaluating the kidney and liver, offering unparalleled soft-tissue contrast and multi-planar capabilities. In current practice, gadolinium-based contrast agents (GBCAs) are routinely administered to detect and characterize focal lesions, assess vascular anatomy, and quantify organ function. However, growing awareness of the risks associated with contrast media — including nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, acute allergic reactions, and gadolinium deposition in the brain — has spurred a major shift in the field. Non-contrast MRI techniques are no longer a niche option but are increasingly recognized as robust first-line approaches for hepatorenal imaging. This article provides a detailed review of the latest advances in non-contrast MRI methods for the kidney and liver, emphasizing their underlying principles, clinical applications, diagnostic performance, and practical considerations for radiology departments.

We will focus on four core techniques that have seen the most significant clinical and technical refinement: diffusion-weighted imaging (DWI), blood oxygen level–dependent (BOLD) imaging, arterial spin labeling (ASL), and advanced relaxometry methods. Each will be discussed separately, with attention to how recent hardware and software innovations are improving image quality, reproducibility, and quantitative accuracy.

Diffusion-Weighted Imaging (DWI): Beyond Qualitative Assessment

Physics and Current Clinical Workflow

Diffusion-weighted imaging quantifies the random Brownian motion of water protons within tissue. In the kidney and liver, tissue microstructure — such as cellular density, tubular integrity, and fibrotic infiltration — directly restricts water diffusivity. The apparent diffusion coefficient (ADC) serves as the principal biomarker; decreased ADC values are associated with tumor hypercellularity, while fibrosis and inflammation also lower diffusivity. Modern clinical DWI is typically performed with single-shot echo-planar imaging (EPI) using at least two b-values (e.g., 50 and 800 s/mm²). Recent advances include the use of parallel imaging, simultaneous multi-slice (SMS) acceleration, and motion-robust sequences that reduce respiratory artifacts, allowing high-quality DWI in free-breathing patients.

Renal Applications of DWI

DWI has emerged as a reliable tool for distinguishing benign from malignant renal masses. Meta-analyses consistently report sensitivity and specificity above 85% for differentiating clear cell renal cell carcinoma (ccRCC) from fat-poor angiomyolipomas, based on ADC thresholds. The technique also aids in characterizing papillary tumors and predicting tumor grade. Beyond lesion characterization, DWI allows assessment of diffuse renal disease. In chronic kidney disease (CKD), cortical ADC correlates inversely with histological fibrosis and GFR decline. Recent work using intravoxel incoherent motion (IVIM) — a multi-b-value DWI model that separates pure diffusion from microperfusion — has added vascular sensitivity, enabling measurement of tubular flow and perfusion fraction in the renal medulla. IVIM is particularly attractive because it does not require contrast and can be repeated serially to monitor response to therapy in pyelonephritis or acute kidney injury.

Hepatic DWI and Fibrosis Staging

In the liver, DWI is increasingly used for lesion detection and fibrosis staging. For focal liver lesions, DWI aids in discriminating hemangiomas, cysts, and metastases from primary hepatocellular carcinoma (HCC). Higher b-value DWI (≥800 s/mm²) improves lesion conspicuity by suppressing background liver signal. For diffuse disease, ADC has been validated against histopathology as a biomarker for liver fibrosis in both chronic hepatitis C and non-alcoholic fatty liver disease (NAFLD). ADC declines progressively with higher fibrosis stage, correlating with collagen deposition and architectural distortion. However, DWI alone has limited accuracy for early fibrosis (F0–F2). To overcome this, researchers have combined DWI with other non-contrast sequences, such as T1 mapping or MR elastography. The development of high-resolution DWI at 3 T, alongside advanced fat-water-separation techniques, is further improving reproducibility and reducing artifacts in cirrhotic livers with iron overload.

Blood Oxygen Level–Dependent (BOLD) MRI: Functional Oxygenation Imaging

Principles and Technical Advances

BOLD imaging exploits the paramagnetic effect of deoxyhemoglobin. In regions of high oxygen consumption or poor perfusion, increased deoxyhemoglobin concentration shortens T2*, causing signal loss on T2*-weighted gradient-echo sequences. The BOLD effect thus provides a surrogate for tissue oxygenation. In the kidney, the corticomedullary oxygen gradient is critical for maintaining concentrating ability and tubular function. Renal BOLD MRI traditionally reports the R2* parameter (1/T2*), which increases with hypoxia. Recent technical refinements include: (1) multi-echo gradient-echo sequences that map R2* across the kidney and liver in a single breath-hold, (2) 3D BOLD acquisitions that cover the entire organ, and (3) respiratory-triggered methods that eliminate motion contamination. Hyperoxia challenge protocols — where patients breathe 100% oxygen — have been used together with BOLD to evaluate the capacity of the kidney to increase oxygenation, revealing insights into diabetic nephropathy and renovascular disease.

Renal BOLD in Practice

BOLD MRI is especially valuable in assessing renal ischemia and evaluating the response to angiotensin-converting enzyme inhibitors or diuretics. In patients with renal artery stenosis, BOLD can detect medullary hypoxia before GFR declines. Studies have shown that R2* values in the medulla correlate with renal blood flow and predict worsening of kidney function. BOLD also has potential in acute conditions: in acute rejection after transplantation, increased medullary R2* correlates with inflammation, while in acute tubular necrosis, the gradient between cortex and medulla is lost. Despite these promising data, routine clinical adoption of BOLD has been limited by lack of standardization. Efforts are underway to create consensus protocols from the ISMRM and ESMRMB, which should improve across-site comparability.

Hepatic BOLD: Inflammation, Fibrosis, and Steatosis

In the liver, BOLD has been used to evaluate hepatic fibrosis and inflammation. Chronic hepatitis leads to increased oxygen consumption by infiltrating immune cells and activated stellate cells, detectable by elevated R2*. A meta-analysis of hepatic BOLD for fibrosis staging reported pooled sensitivity of 80% and specificity of 75% for F≥2 fibrosis, though performance is lower than MR elastography. However, BOLD can be added to a standard non-contrast liver protocol at no extra cost and can be performed in a few minutes. A more recent application is to assess hepatic steatosis: fat deposition itself does not directly alter R2*, but combined with T2* mapping, BOLD can separate the effects of iron and fat. In patients with NAFLD, BOLD-derived R2* correlates with hepatic iron content, which is often elevated in metabolic syndrome. This combined approach helps differentiate pure steatosis from steatohepatitis with iron overload — valuable for early risk stratification.

Arterial Spin Labeling (ASL): Quantitative Perfusion Without Contrast

How ASL Works and Recent Innovations

Arterial spin labeling is a completely non-invasive method for measuring tissue perfusion using magnetically tagged water protons in arterial blood as an endogenous tracer. In the kidney and liver, ASL typically uses a single inversion pulse to label inflowing blood in the major feeding arteries (e.g., renal artery or celiac axis), followed by a delay (post-label delay) to allow labeled blood to reach the parenchyma. The resulting perfusion-weighted images are subtracted from control images and fitted to a kinetic model to estimate renal blood flow (RBF) or hepatic perfusion in milliliters per 100 g per minute. Recent innovations include: (1) background suppression schemes that reduce static tissue signal, improving SNR, (2) 3D fast spin-echo readouts (e.g., 3D GRASE) that allow whole-organ coverage, and (3) multi-phase ASL that can separately measure cortical and medullary perfusion. Pulsed ASL (PASL) and pseudo-continuous ASL (PCASL) are the most common methods; PCASL offers higher SNR and is preferred for abdominal applications when field strength (≥3 T) and hardware permit.

Renal ASL: Monitoring GFR and Vascular Disease

Renal ASL is among the most mature non-contrast perfusion techniques. It provides absolute quantification of RBF, which is tightly coupled to GFR. In hypertensive patients, reduced cortical perfusion precedes structural damage, and ASL can identify asymmetrical perfusion in renal artery stenosis. The technique is also used to monitor transplant perfusion — a drop in RBF on ASL can indicate rejection or delayed graft function before biopsy. In diabetic nephropathy, ASL reveals early perfusion declines even when GFR is still normal. A key advantage is the ability to perform repeated measures without contrast: this allows stress testing (e.g., after captopril) and longitudinal follow-up. A 2022 consensus paper by the ISMRM ASL Study Group endorsed a standardized renal ASL protocol for multicenter trials, and several vendors now provide FDA-cleared ASL packages for abdominal use.

Hepatic ASL: Challenges and Progress

Hepatic ASL is more challenging than renal ASL due to respiratory motion, the dual blood supply (hepatic artery and portal vein), and the need for longer post-label delays to allow tracer delivery through the portal circulation. Nevertheless, recent technical developments — especially the use of respiratory-triggered PCASL with multi-shot 3D readouts — have made liver perfusion imaging feasible. Quantitative hepatic perfusion derived from ASL correlates well with contrast-enhanced perfusion CT and 15O-water PET. Applications include assessing diffuse liver disease: in cirrhosis, total liver perfusion is decreased, and the arterial fraction increases. In HCC, tumors show high and heterogeneous perfusion that can be distinguished from adjacent liver parenchyma. A 2021 study in Radiology demonstrated that ASL perfusion measures could differentiate regenerative nodules from dysplasia in cirrhotic patients with a sensitivity of 88%. While not yet a replacement for contrast-enhanced MRI for lesion detection, ASL adds functional information that complements DWI and T2-weighted imaging.

Emerging Non-Contrast Techniques: T1 Mapping, T2 Mapping, and MRE

T1 and T2 Relaxometry

Native T1 mapping (without contrast) and T2 mapping are quantitative MRI techniques that probe tissue composition. In the liver, native T1 values correlate strongly with fibrosis and inflammation — the T1 time increases as extracellular matrix expands. Combined with T2* mapping to correct for iron, the model-free parameter “cT1” (corrected T1) has been validated for staging of NAFLD and fibrosis in large multi-center trials. For the kidney, native T1 mapping can detect fibrosis and edema; high cortical T1 in CKD patients correlates with interstitial expansion. T2 mapping is less established for kidney but shows promise in detecting acute pyelonephritis. The addition of these sequences to a non-contrast protocol adds only 2–3 minutes of scan time and can provide quantitative cutoffs for disease stratification.

MR Elastography (MRE)

MR elastography is the most accurate non-contrast method for assessing liver fibrosis, with sensitivity over 90% for advanced fibrosis. MRE works by propagating mechanical shear waves through the liver and measuring their speed, which increases with tissue stiffness (fibrosis). Modern MRE sequences use 60–80 Hz vibrations, 2D gradient-echo or spin-echo EPI readouts, and automated wave inversion algorithms. While traditionally requiring specific hardware (an active driver), recent developments allow MRE to be performed with passive drivers placed under the patient, making it easier to implement. For the kidney, MRE is still experimental but has shown that renal stiffness increases with fibrosis and decreases with obstructive nephropathy. A challenge is that kidney MRE is affected by blood pressure and urine flow, so protocols must be standardized carefully.

Clinical Implementation: Strategies and Pitfalls

Moving non-contrast MRI into routine hepatorenal imaging requires protocol optimization, radiologist training, and an understanding of each technique's limitations. For many institutions, a streamlined non-contrast liver protocol may include: axial T2-weighted HASTE, DWI (b50, b800), T1-weighted in/out-of-phase, native T1 mapping, and 2D MRE. For renal imaging: axial T2, DWI, ASL, BOLD, and T1 mapping. When applied in patients with contraindications to gadolinium (eGFR <30 mL/min/1.73m², prior allergic reaction, or patient preference), these protocols can replace 80–90% of contrast-enhanced studies, with some diagnostic loss only for detecting small (<1 cm) hypervascular metastases or for evaluating complex vascular anatomy like active bleeding. Many radiology departments are now adopting ACR guidance that endorses non-contrast alternatives as first-line in at-risk populations.

Limitations to Keep in Mind

  • DWI: Subject to susceptibility artifacts from air, stents, and iron; ADC can be confounded by fat, cell necrosis, and edema.
  • BOLD: R2* is influenced by iron, hematocrit, and blood volume — not purely oxygenation. Requires careful modeling.
  • ASL: Lower SNR than dynamic contrast-enhanced (DCE) perfusion; may miss hypervascular lesions with very short transit times; still limited availability on older scanners.
  • MRE: Failure rate up to 10% in obese patients or those with massive ascites; different vendors use different vibration frequencies, affecting stiffness cutoffs.

Future Directions and Research

The next wave of innovation will likely focus on (a) deep learning reconstruction to accelerate acquisition and reduce artifacts, (b) simultaneous multi-parametric acquisition — e.g., combined DWI and BOLD in a single sequence to save time, (c) motion artefact removal using navigator-free self-gating, and (d) dedicated synthetic contrast imaging where native sequences are used to generate virtual contrast-enhanced images (e.g., using diffusion to predict T1 shortening). As these methods mature, the goal is to achieve a comprehensive non-contrast MRI exam that can replace gadolinium-enhanced studies for most clinical indications. International registries are collecting data on multi-center reproducibility of non-contrast biomarkers, and radiologists should monitor NIDDK's Kidney MRI Atlas and similar initiatives for evolving standards.

Conclusion

Non-contrast MRI of the kidney and liver has advanced from a rudimentary alternative to a sophisticated toolkit capable of providing both structural and functional information. DWI, BOLD, ASL, T1/T2 mapping, and MRE each offer unique and complementary insights — from cellularity and oxygenation to perfusion and stiffness. With ongoing technical improvements, validated protocols, and growing clinical evidence, these methods are ready for wider adoption. For patients with contraindications to contrast agents or those requiring repeated imaging, non-contrast MRI offers a safe, effective, and increasingly accurate option. Radiologists and referring clinicians should be aware of the capabilities and limitations of each technique to choose the most appropriate approach for their patients.